文献速递类风湿关节炎

类风湿关节炎TNF抑制剂反应与CD40、CD39数量性状位点的关联

Association of response to TNF inhibitors in rheumatoid arthritis with quantitative trait loci for CD40 and CD39.
PubMed 文献 · Ann Rheum Dis · 2019-04-29

本研究在2938例基因分型类风湿关节炎患者中,用全基因组关联研究汇总统计构建位点特异性评分,评估其与TNF抑制剂反应(肿胀关节数变化ΔSJC、红细胞沉降率变化ΔESR)的关联。结果发现ΔSJC与CD40位点RA评分(p=0.0004)及CD4 T细胞CD39表达评分呈负相关(p=0.00005),但基因型评分整体预测能力有限,模型解释的表型方差不足1%。

要点

  • ΔSJC与CD40位点RA评分显著相关(p=0.0004)。
  • ΔSJC与CD4 T细胞CD39表达评分呈负相关(p=0.00005)。
  • CD39负相关在联合甲氨蝶呤组更强,TNFi单药组消失。

核心结论

  • ΔSJC与CD40位点RA评分及CD4 T细胞CD39表达评分存在关联,但基因型评分对TNFi反应的预测能力有限。

研究设计与样本

  • 研究纳入2938例基因分型个体,构建37个RA评分、19个免疫细胞性状评分及93个基因表达或甲基化评分。
  • 采用惩罚回归模型结合交叉验证评估多变量关联。

主要发现

  • ΔSJC与CD40位点RA评分关联p=0.0004。
  • ΔSJC与CD4 T细胞CD39表达评分呈负相关,p=0.00005。
  • 既往报告的CD39表达与甲氨蝶呤反应关联方向相反。
  • 按合并甲氨蝶呤分层,CD39负相关在联合治疗组更强,TNFi单药组消失。
  • 基因型评分模型解释的表型方差不足1%。

关键数值与推荐

  • ΔSJC与CD40位点RA评分关联p=0.0004。
  • ΔSJC与CD4 T细胞CD39表达评分关联p=0.00005。

临床怎么用

  • CD39与CD40通路可能成为药物靶点相关线索。
  • 基因型评分目前不足以用于TNFi反应分层。
  • 合并甲氨蝶呤可能影响CD39相关关联的解读。

局限性

  • CD39性状关联难以解读,因RA患者常在甲氨蝶呤治疗失败后使用TNFi。
  • 基因型评分预测TNFi反应能力有限,模型解释方差不足1%。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: We sought to investigate whether genetic effects on response to TNF inhibitors (TNFi) in rheumatoid arthritis (RA) could be localised by considering known genetic susceptibility loci for relevant traits and to evaluate the usefulness of these genetic loci for stratifying drug response. METHODS: We studied the relation of TNFi response, quantified by change in swollen joint counts ( Δ SJC) and erythrocyte sedimentation rate ( Δ ESR) with locus-specific scores constructed from genome-wide assocation study summary statistics in 2938 genotyped individuals: 37 scores for RA; scores for 19 immune cell traits; scores for expression or methylation of 93 genes with previously reported associations between transcript level and drug response. Multivariate associations were evaluated in penalised regression models by cross-validation. RESULTS: We detected a statistically significant association between Δ SJC and the RA score at the CD40 locus (p=0.0004) and an inverse association between Δ SJC and the score for expression of CD39 on CD4 T cells (p=0.00005). A previously reported association between CD39 expression on regulatory T cells and response to methotrexate was in the opposite direction. In stratified analysis by concomitant methotrexate treatment, the inverse association was stronger in the combination therapy group and dissipated in the TNFi monotherapy group. Overall, ability to predict TNFi response from genotypic scores was limited, with models explaining less than 1% of phenotypic variance. CONCLUSIONS: The association with the CD39 trait is difficult to interpret because patients with RA are often prescribed TNFi after failing to respond to methotrexate. The CD39 and CD40 pathways could be relevant for targeting drug therapy.

来源:Ann Rheum Dis,查看原文。版权归原作者所有。

引用

  1. Spiliopoulou A, Colombo M, Plant D, et al. Association of response to TNF inhibitors in rheumatoid arthritis with quantitative trait loci for CD40 and CD39. Ann Rheum Dis. 2019. PMID: 31036624. doi:10.1136/annrheumdis-2018-214877

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。